IMProving the quality of life for rAdiation therapy prostate Cancer patienTs (IMPACT)

Not Applicable

• Conditions: Prostate cancer; Cancer - Prostate

• Registration Number: ACTRN12624000106538
• Lead Sponsor: South Western Sydney Local Health District

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2024-02-07
• Last Update Posted: 12 February 2024

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: Male
• Target Recruitment: 60

Inclusion Criteria

1.Prostate cancer patients that receive radiotherapy treatment for prostate with current treatment protocol used within Liverpool and Macarthur cancer therapy centres.
2.Patients implanted with three prostate radio opaque markers
3.Patients receiving definitive radiotherapy to the prostate

Exclusion Criteria

Patients with hip prosthesis

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Delivered dose to the prostate CTV and organs at risk will be assessed. This will be assessed as a composite primary outcome.[CT scans, KV images acquired by Seedtracker At the end of radiotherapy treatment.]

Secondary Outcome Measures

Name	Time	Method
The patients’ Quality of Life (QoL) during and after prostate RT will be assessed.[Expanded Prostate Cancer Index Composite (EPIC) questionnaire Assessed at the commencement, middle and end of treatment. Assessed at 3, 6, 12, 24, 36 and 60 months after the completion of treatment.];The patient's biochemical control will be assessed.[PSA (prostate specific antigen) blood test measurements. 36 months and 60 months after treatment.]